Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen AS, Batsis JÁ
Diabetes. 2025:dbi250004.
Leggi
Stem cell-derived pancreatic beta cells: a step closer to functional diabetes treatment?
Ogieuhi IJ, Agbo CE, Ajekiigbe VO, et al.
BMC Endocr Disord. 2025;25(1):181.
Leggi
Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an Endocrine Society Scientific Statement
Michels AW, Brusko TM, Evans-Molina C, et al.
J Clin Endocrinol Metab. 2025:dgaf267.
Leggi
Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity
Lin HT, Tsai YF, Liao PL, et al.
JAMA Netw Open. 2025;8(7):e2521016.
Leggi
Association between remnant cholesterol and low-density lipoprotein cholesterol discordance and type 2 diabetes or prediabetes: results from NHANES
Xin Y, Wang Y, Shu Y, Liang H, Yang Y
BMC Endocr Disord. 2025;25(1):168.
Leggi
Early worsening of diabetic retinopathy in individuals with type 2 diabetes treated with tirzepatide: a real-world cohort study
Buckley AJ, Tan GD, Gruszka-Goh M, et al.
Diabetologia. Pub. online 10 Jul 2025.
Leggi
Dapagliflozin’s impact on hormonal regulation and ketogenesis in type 1 diabetes: a randomised controlled crossover trial
Gübeli A, Steiner N, Limacher A, et al.
Diabetologia. Pub. online 9 Jul 2025.
Leggi
Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: an observational study comparing matched cohorts
Caruso PD, Angelino S, Matrone R, et al.
Diabetes Obes Metab. Pub. online 7 Jul 2025.
Leggi
Time to progression to proliferative diabetic retinopathy in patients with type 2 diabetes
Kim IM, Radgoudarzi N, Chen EM, et al.
JAMA Netw Open. 2025;8(7):e2521150.
Leggi
The effects of non-insulin anti-diabetic medications on the diabetic microvascular complications: a systematic review and meta-analysis of randomized clinical trials
Wen S, Yuan Y, Li Y, et al.
BMC Endocr Disord. 2025;25(1):179.
Leggi